Hikma Pharmaceuticals Forecast, price target & analysts
Hikma Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Hikma Pharmaceuticals Classifications & Recommendation:
Hikma Pharmaceuticals Price Target
| Target Price | £25.55 |
| Price | £15.77 |
| Potential |
62.02%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Hikma Pharmaceuticals 2026 .
The average Hikma Pharmaceuticals target price is £25.55.
This is
62.02%
register free of charge
£29.93
89.76%
register free of charge
£19.91
26.27%
register free of charge
|
|
| A rating was issued by 20 analysts: 17 Analysts recommend Hikma Pharmaceuticals to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Hikma Pharmaceuticals stock has an average upside potential 2026 of
62.02%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2030
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion £ | 2.40 | 2.60 |
| 9.77% | 8.46% | |
| EBITDA Margin | 22.85% | 26.26% |
| 7.49% | 14.95% |
14 Analysts have issued a sales forecast Hikma Pharmaceuticals 2025 . The average Hikma Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an Hikma Pharmaceuticals EBITDA forecast 2025. The average Hikma Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share £ | 1.22 | 1.77 |
| 87.69% | 45.08% | |
| P/E | 9.03 |
14 Analysts have issued a Hikma Pharmaceuticals forecast for earnings per share. The average Hikma Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Hikma Pharmaceuticals...
Current Hikma Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Jefferies |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| JP Morgan Cazenove |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Peel Hunt Limited |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Nov 06 2025 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Oct 16 2025 |
| Deutsche |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
| JP Morgan Cazenove |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Jefferies:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
JP Morgan Cazenove:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Peel Hunt Limited:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Nov 06 2025 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Oct 16 2025 |
|
Locked
Deutsche:
Locked
➜
Locked
|
Aug 12 2025 |
|
Locked
JP Morgan Cazenove:
Locked
➜
Locked
|
Aug 08 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
